GW's epilepsy timetable eclipses Sativex cancer miss

Investors ignored a Phase III trial miss for Sativex in cancer pain on Thursday, pushing up shares of GW Pharmaceuticals plc (NASDAQ:GWPH; LSE:GWP) by 13% on NASDAQ after

Read the full 284 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE